Intramuscular Versus Intravenous Prophylactic Oxytocin for Hemorrhage After Vaginal Delivery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

2 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-02-28

Study Completion Date

2015-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Intramuscular versus intravenous prophylactic oxytocin for the third stage of labour following vaginal delivery: A randomised controlled trial

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

IV vs IM Oxytocin in the Third Stage of Labor for Prevention of Postpartum Hemorrhage

NCT01608958

Postpartum Hemorrhage

COMPLETED NA

Intraumbilical Vein Injection of Oxytocin in Routine Practice for Active Management of the Third Stage of Labor

NCT01094028

Labor

COMPLETED PHASE3

Efficacy of Four Different Treatment Regimes on Postpartum Hemorrhage

NCT05467462

Postpartum Hemorrhage

COMPLETED NA

When and How to Administer Oxytocin for Active Management of Third Stage of Labour

NCT01954186

Postpartum Bleeding

COMPLETED NA

Cervical Traction vs. Active Management of 3rd Stage of Labor

NCT04747015

Post Partum Hemorrhage

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Prevention of postpartum haemorrhage is essential in the pursuit of improved health care for women. In this study investigators aimed to compare intramuscular oxytocin with intravenous oxytocin for the routine prevention of postpartum haemorrhage in women who deliver vaginally.In some countries, intravenous access can not be provided easily . Intramuscular application is faster , easier and tougher enforcement requires less skill and equipment . For this reason, less educated , which can be applied by those offering health services .

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postpartum Hemorrhage

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

intravenous 10 ıu oxytocin

group which 2 ampul prophylactic oxytocin given for third stage of labour intravenously after vaginal delivery

Group Type ACTIVE_COMPARATOR

intarvenous and intramusculer 10 IU oxytocin

Intervention Type DRUG

intarvenous and intramusculer 10 IU oxytocin

intramusculer 10 ıu oxytocin

group which oxytocin administered intramusculary after vaginal delivery

Group Type EXPERIMENTAL

intarvenous and intramusculer 10 IU oxytocin

Intervention Type DRUG

intarvenous and intramusculer 10 IU oxytocin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

intarvenous and intramusculer 10 IU oxytocin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Research volunteers, the undersigned, pregnant women
2. Only with vaginal delivery (episiotomy and perineal tears can)
3. \> 34 weeks or more will be
4. Cephalic presentation will be
5. At low risk of postpartum hemorrhage

Exclusion Criteria

1. \<18 years
2. Multiple pregnancies
3. The presence of uterine myoma
4. Having postpartum hemorrhage in previous pregnancies
5. Placenta previa, polyhydramnios
6. More than four parity
7. Fetal macrosomia
8. Hb \<9mg/dl
9. preeclampsia
10. Uterine anomalies
11. Receiving anticoagulant therapy, suspected coagulopathy
12. \> 42 weeks of pregnancy
13. Oxytocin allergy -

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No